Johnson & Johnson reports 75% tumor response rate in advanced prostate cancer with JNJ-6143, a first-in-class RIPTAC™ molecule
Johnson & Johnson reported Phase 1 results for JNJ-6143, a first-in-class once-daily oral RIPTAC molecule, in heavily pre-treated advanced prostate cancer: 75% of patients with measurable disease achieved a confirmed complete or partial response. At the selected 50 mg dose, 77% of patients achieved a confirmed PSA reduction of at least 50%, including 48% with reductions of at least 90%, and 71% remained on treatment at a median follow-up of 5.6 months. Adverse events were mostly mild to moderate; the 50 mg dose advances into a Phase 2 study in metastatic prostate cancer.
Key figures
- Drug Name
- JNJ-6143 (formerly HLD-0915)
- Phase Of Trial
- Phase 1
- Psa50 rate
- 77% at 50 mg dose
- Psa90 rate
- 48%
- Tumor response rate
- 75% (12 of 16 patients with measurable disease, RECIST complete/partial response)
- Patients on treatment
- 71%
- Median followup months
- 5.6
- Median prior therapies
- 4
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.